MCID: SMT001
MIFTS: 45

Somatization Disorder

Categories: Mental diseases

Aliases & Classifications for Somatization Disorder

MalaCards integrated aliases for Somatization Disorder:

Name: Somatization Disorder 12 75 15 72 33
Somatoform Disorders 44 33
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorder 72
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD9CM 35 300.81
MeSH 44 D013001
SNOMED-CT 68 60368009 9514005
ICD10 33 F45 F45.0
UMLS 72 C0037650 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as somatoform disorders, is related to dissociative seizures and psychogenic movement, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is DCXR (Dicarbonyl And L-Xylulose Reductase). The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and testes, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 75 Somatization disorder is a mental disorder characterized by recurring, multiple, and current, clinically... more...

Related Diseases for Somatization Disorder

Diseases related to Somatization Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 dissociative seizures 11.5
2 psychogenic movement 11.5
3 social phobia 10.8
4 somatoform disorder 10.8
5 bruxism 10.4
6 phobia, specific 10.1
7 depersonalization/derealization disorder 10.1
8 personality disorder 10.1
9 anxiety 10.1
10 fibromyalgia 10.1
11 depression 10.1
12 chronic pain 10.1
13 alzheimer disease 10.0
14 multiple system atrophy 1 10.0
15 parkinson disease, late-onset 10.0
16 supranuclear palsy, progressive, 1 10.0
17 macular dystrophy with central cone involvement 10.0
18 obsessive-compulsive personality disorder 10.0
19 lyme disease 10.0
20 dysthymic disorder 10.0
21 sick building syndrome 10.0
22 tic disorder 10.0
23 complex regional pain syndrome 10.0
24 adjustment disorder 10.0
25 fainting 10.0
26 tremor 10.0
27 persistent idiopathic facial pain 10.0
28 mental depression 10.0
29 major depressive disorder 10.0
30 chronic fatigue syndrome 10.0
31 irritable bowel syndrome 10.0
32 hypochondriasis 10.0
33 conversion disorder 10.0
34 antisocial personality disorder 9.9
35 severe combined immunodeficiency 9.9
36 hemifacial spasm, familial 9.9
37 tobacco addiction 9.9
38 trigeminal neuralgia 9.9
39 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
40 body mass index quantitative trait locus 11 9.9
41 frontotemporal dementia 9.9
42 body mass index quantitative trait locus 9 9.9
43 macular degeneration, age-related, 1 9.9
44 body mass index quantitative trait locus 8 9.9
45 body mass index quantitative trait locus 4 9.9
46 body mass index quantitative trait locus 10 9.9
47 breath-holding spells 9.9
48 body mass index quantitative trait locus 7 9.9
49 smoking as a quantitative trait locus 3 9.9
50 body mass index quantitative trait locus 12 9.9

Comorbidity relations with Somatization Disorder via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Anxiety
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

MGI Mouse Phenotypes related to Somatization Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.46 ALX3 CRH LIFR SCGB1A1
2 growth/size/body region MP:0005378 9.35 ALX3 CRH LIFR NDUFS3 SCGB1A1
3 homeostasis/metabolism MP:0005376 9.02 ALX3 CRH LIFR NDUFS3 SCGB1A1

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Cycloserine Approved Phase 4 68-41-7 6234 401
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Tibolone Approved, Investigational Phase 4 5630-53-5
5
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Histamine Approved, Investigational Phase 4 51-45-6 774
9
Flunarizine Approved Phase 4 52468-60-7 941361
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
16
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
17 Mosapride Investigational Phase 4 112885-41-3
18 Renal Agents Phase 4
19 Antitubercular Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Anti-Infective Agents, Urinary Phase 4
22 Antimetabolites Phase 4
23 Tranquilizing Agents Phase 4
24 Anti-Anxiety Agents Phase 4
25 calcium channel blockers Phase 4
26 Calcium, Dietary Phase 4
27 Contraceptives, Oral Phase 4
28 Antihypertensive Agents Phase 4
29 Contraceptive Agents, Male Phase 4
30 Estrogens Phase 4
31 Androgens Phase 4
32 Selective Estrogen Receptor Modulators Phase 4
33 Contraceptive Agents Phase 4
34 Anabolic Agents Phase 4
35 Estrogen Receptor Modulators Phase 4
36 Estradiol 17 beta-cypionate Phase 4
37
Medroxyprogesterone Phase 4 520-85-4 10631
38 Antineoplastic Agents, Hormonal Phase 4
39 Estradiol 3-benzoate Phase 4
40 Androgen Antagonists Phase 4
41 Histamine H1 Antagonists Phase 4
42 Histamine Antagonists Phase 4
43
Histamine Phosphate Phase 4 51-74-1 65513
44 Vasodilator Agents Phase 4
45 Antidepressive Agents Phase 4
46 Neurotransmitter Agents Phase 4
47 Neurotransmitter Uptake Inhibitors Phase 4
48 Psychotropic Drugs Phase 4
49 Serotonin Uptake Inhibitors Phase 4
50 abobotulinumtoxinA Phase 4

Interventional clinical trials:

(show top 50) (show all 244)
# Name Status NCT ID Phase Drugs
1 Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome Completed NCT01764464 Phase 4 Gralise®;Placebo
2 A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome Completed NCT00663897 Phase 4 lansoprazole;mosapride
3 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
5 The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4 Tibolone;Estradiol & medroxyprogesterone acetate
6 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4 flunarizine and/or pregabalin
7 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
8 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
9 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
10 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
11 A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment Withdrawn NCT00673972 Phase 4
12 An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome Unknown status NCT01134289 Phase 3
13 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Unknown status NCT02390505 Phase 3 Vitamin C;Placebo
14 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
15 Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck) Unknown status NCT00949065 Phase 3
16 Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
17 Treatment of Somatization in Primary Care Completed NCT00050583 Phase 3
18 Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care. Completed NCT00132197 Phase 2, Phase 3
19 Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care) Completed NCT00368212 Phase 3
20 A 16-week Prospective Randomised Double-blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation. Completed NCT00246142 Phase 3
21 Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1 Completed NCT00166452 Phase 3 Lenalidamide
22 Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner Completed NCT00130988 Phase 3
23 Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
24 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
25 Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof Completed NCT01119469 Phase 3
26 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
27 Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
28 Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I Completed NCT00817128 Phase 2, Phase 3
29 A Prospective Randomized Study Comparing the Outcome of Electrical Stimulation of Vastus Medialis Obliquus Muscle and Physical Therapy vs Only Physical Therapy But no Electrical Stimulation in Patients With Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
30 Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome Recruiting NCT03463915 Phase 3 Bladder instillation WITH triamcinolone acetonide;Bladder instillation WITHOUT triamcinolone acetonide
31 Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial Recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
32 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Active, not recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
33 A Prospective Randomized Controlled Pilot Study Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome Enrolling by invitation NCT03879538 Phase 3 Nitrous Oxide;Oxygen
34 Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS) Terminated NCT03560986 Phase 3 Neridronic acid;Placebo
35 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
36 Pharmacovigilance in Gerontopsychiatric Patients Terminated NCT02374567 Phase 3 Phenobarbital;Phenytoin;Carbamazepine;Oxcarbazepine;Valproic Acid;Lamotrigine;Topiramate;Gabapentin;Levetiracetam;Pregabalin;Lacosamide;Clonazepam;Biperiden;Levomepromazine;Fluphenazine;Perphenazine;Perazine;Thioridazine;Haloperidol;Melperone;Pipamperone;Bromperidol;Benperidol;Sertindole;Ziprasidone;Flupentixol;Chlorprothixene;Zuclopenthixol;Fluspirilene;Pimozide;Clozapine;Olanzapine;Quetiapine;Sulpiride;Tiapride;Amisulpride;Prothipendyl;Risperidone;Aripiprazole;Paliperidone;Diazepam;Oxazepam;Lorazepam;Bromazepam;Clobazam;Alprazolam;Hydroxyzine;Buspirone;Chloral Hydrate;Flurazepam;Nitrazepam;Triazolam;Lormetazepam;Temazepam;Midazolam;Brotizolam;Zopiclone;Zolpidem;Zaleplon;Melatonin;Clomethiazole;Diphenhydramine;Promethazine;Imipramine;Clomipramine;Opipramol;Trimipramine;Amitriptyline;Nortriptyline;Doxepin;Maprotiline;Amitriptyline oxide;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Escitalopram;Tranylcypromine;Moclobemide;Mianserin;Trazodone;Mirtazapine;Bupropion;Venlafaxine;Reboxetine;Duloxetine;Agomelatine;Pyritinol;Piracetam;Donepezil;Rivastigmine;Galantamine;Memantine;Nicergoline;Acamprosate;Lithium
37 Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient. Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
38 Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb Unknown status NCT00377468 Phase 2 Delta9-Tetrahydrocannabinol
39 Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial Unknown status NCT02613247 Phase 2
40 Cognitive Affective Behavior Therapy for Somatization Completed NCT00149760 Phase 2
41 Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3) Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
42 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
43 Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons Completed NCT01187797 Phase 1, Phase 2
44 A Phase II, Multicentre, Randomised, Double-blind, Parallel and Controlled With Placebo Pilot Study to Evaluate the Efficacy and Safety of a Single Dose of Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment, in Patients With Primary Myofascial Syndrome of Cervical and Dorsal Localisation Completed NCT00149240 Phase 2
45 A Phase II Multicentre Multinational Prospective Randomised Double-blind Placebo-controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome Completed NCT00134810 Phase 2
46 A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Completed NCT03282318 Phase 2 ASP6294;Placebo
47 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
48 A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway Completed NCT01882543 Phase 2 AQX-1125;Placebo
49 Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial. Completed NCT01691170 Phase 1, Phase 2
50 A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed NCT00067743 Phase 2 Lenalidomide

Search NIH Clinical Center for Somatization Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


St. John's Wort

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

41
Prostate, Brain, Testes, Spinal Cord, Bone, Dorsal Root Ganglion, Eye

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 1914)
# Title Authors PMID Year
1
Re: Jing et al., the efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. 38
30819582 2019
2
Individuals with currently untreated mental illness: causal beliefs and readiness to seek help. 38
29335036 2019
3
Sociomedical problems of overwork-related deaths and disorders in Japan. 38
30977205 2019
4
Hospital length of stay among older people treated with flexible and integrative psychiatric service models in Germany. 38
31276239 2019
5
Profile of home nursing clients with mental health diagnoses: Epidemiological analysis of Australian community home nursing data. 38
30815957 2019
6
Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. 38
30685531 2019
7
Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective study. 38
30923956 2019
8
Evaluation of Risk Factors for ADHD and Co-Morbid Psychiatric Disorders Among the Parents of Children With ADHD. 38
27009925 2019
9
Early maladaptive schemas in patients with somatoform disorders and somatization. 38
30836437 2019
10
Parent-youth conflict as a predictor of depression in adulthood: a 15-year follow-up of a community-based cohort. 38
31302772 2019
11
Voxel-based global-brain functional connectivity alterations in first-episode drug-naive patients with somatization disorder. 38
31121532 2019
12
Deficits in Theory of Mind and Emotional Awareness in Somatoform Disorders. 38
31391671 2019
13
Mindfulness and Acceptance-Based Group Therapy: An Uncontrolled Pragmatic Pre-Post Pilot Study in a Heterogeneous Population of Female Prisoners. 38
31238758 2019
14
Health-related life events in patients with somatic symptom disorders: A case control study. 38
30969143 2019
15
A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. 38
31195993 2019
16
The prognosis of functional limb weakness: a 14-year case-control study. 38
31167232 2019
17
The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS). 38
31248601 2019
18
Small atrial septal defects are associated with psychiatric diagnoses, emotional distress, and lower educational levels. 38
31136098 2019
19
Physical activity is indirectly associated with pain in college women through associations with somatization and panic disorder symptoms: a cross-sectional study. 38
30905543 2019
20
The Neuroanatomy of Somatoform Disorders: A Magnetic Resonance Imaging Study. 38
30119840 2019
21
Implementation of outcome measurement (HoNOS) in an outpatient psychiatric clinic in Sligo/Leitrim mental health service. 38
30980222 2019
22
Posttraumatic stress reactions of underground drivers after suicides by jumping to arriving trains; feasibility of an early stepped care outpatient intervention. 38
30963791 2019
23
The prevalence and its correlates of somatization disorder at a quaternary mental health centre. 38
30947092 2019
24
Emotional dysregulation subgroups in patients with adult Attention-Deficit/Hyperactivity Disorder (ADHD): a cluster analytic approach. 38
30948735 2019
25
Somatization, Depression, and Anxiety Disorders in a Rhinology Practice. 38
30947506 2019
26
Epigenetics-by-sex interaction for somatization conferred by methylation at the promoter region of SLC6A4 gene. 38
30201454 2019
27
Overall Care-Seeking Pattern and Gender Disparity at a Specialized Mental Hospital in Bangladesh. 38
31213953 2019
28
The prevalence of mental disorders in Taiwanese prisons: a nationwide population-based study. 38
30310945 2019
29
Utilization of Emergency Psychiatry Service in a Tertiary Care Centre in North Eastern India: A Retrospective Study. 38
30983666 2019
30
Epidemiology of mental disorders during pregnancy and link to birth outcome: a large-scale retrospective observational database study including 38,000 pregnancies. 38
30734864 2019
31
Differential Diagnosis between Anomalous Experiences and Dissociation Disorder Using the Dissociative Disorders Interview Schedule (DDIS). 38
30058948 2019
32
Functional neuroimaging in patients presenting with somatoform disorders: A model for investigating persisting symptoms after tick bites and post-treatment Lyme disease syndrome? 38
30736992 2019
33
Differential diagnostic challenge - Eating disorder, gastroparesis or somatization disorder? - Case report. 38
30948699 2019
34
A study of psychiatric morbidity among school going adolescents. 38
30992616 2019
35
Factors influencing adherence to therapeutic recommendations made after diagnostic reassessment of medically unexplained symptoms in children and adolescents. 38
30818976 2019
36
The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. 38
30368076 2019
37
Detecting DSM-5 somatic symptom disorder: criterion validity of the Patient Health Questionnaire-15 (PHQ-15) and the Somatic Symptom Scale-8 (SSS-8) in combination with the Somatic Symptom Disorder - B Criteria Scale (SSD-12). 38
30729902 2019
38
[Non-epileptic psychogenic seizures: a renewal approach of conversion disorders]. 38
30983230 2019
39
[Definition of somatoform disorders: somatic symptoms or mental symptoms?] 38
30983226 2019
40
[Somatoform disorders: 10 key messages]. 38
30983233 2019
41
Addressing Mental Health Concerns in Primary Care: Practices Among Medical Residents in a Rural Setting. 38
30758698 2019
42
Frequency of psychiatric disorders in nonemergent admissions to emergency department. 38
30729944 2019
43
[Somatoform disorders: make the diagnosis, avoid aggravating, consider the patient's suffering]. 38
30983225 2019
44
[Comorbid Mental Disorders in Gastroenterology and Hepatology: Prevalence and Psychosocial Needs in Tertiary Care]. 38
29439279 2019
45
Prevalence and determinants of symptoms of antenatal common mental disorders among women who had recently experienced an earthquake: a systematic review. 38
30691424 2019
46
[The role of transcranial electrostimulation in the treatment of psychosomatic disorders in industrial workers]. 38
31095128 2019
47
[Impairments of cognitive control in patients with somatoform disorders and their treatment]. 38
31156219 2019
48
[Depressive and somatoform disorders in persons with a Turkish migration background in Germany]. 38
30187080 2019
49
Clinical Practice Guidelines for the management of Somatoform Disorders in Children and Adolescents. 38
30745699 2019
50
[A multiple linear model of help-seeking behavior in patients with depressive and neurotic disorders]. 38
31006786 2019

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

GO Terms for Somatization Disorder

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 8.96 SCGB1A1 CRH
2 response to cytokine GO:0034097 8.62 SCGB1A1 LIFR

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....